Journal News

JBC: Targeting semen amyloid fibrils to reduce HIV infectivity

Courtney Chandler
Oct. 1, 2016

The human immunodeficiency virus, which attacks the immune system, affects more than 1.2 million people in the U.S. There aren’t any vaccines or cures. Instead, microbicides are used to help protect against the transmission of HIV from person to person. However, the process of transmission isn’t understood fully and can involve both viral and human factors that promote infection.

Gallic acid, or GA, coats the surfaces of amyloid fibrils in semen to prevent HIV infectivity enhancement and coats the peptide precursors to prevent fibril formation.IMAGE COURTESY OF JOSIE LORICCO

In a recent paper published in the Journal of Biological Chemistry, Nadia Roan of the University of California, San Francisco, and George Makhatadze of Rensselaer Polytechnic Institute described a small molecule that prevents a specific human factor from increasing the ability of HIV to cause infection.

Researchers know that the virus itself has many factors that help it infect new hosts. There are also human factors that play a role in the transmission of HIV and a person’s susceptibility to infection. One of these factors is the ordered accumulations of misfolded proteins called amyloid fibrils. These fibrils occur naturally in human semen and have been shown to increase HIV infectivity and decrease the effectiveness of anti-HIV microbicide treatments.

The infection-promoting fibrils have been observed in the semen of both healthy and HIV-infected men. Therefore, researchers want to identify compounds that disrupt the formation of these fibrils or rid them of their infectivity-enhancing properties and reduce the sexual transmission of the virus through semen.

The investigators, led by graduate student Josie LoRicco of Rensselaer Polytechnic Institute, used a screen of small molecules to identify compounds that altered the properties of specific amyloid fibrils in semen. One molecule that came out of the screen, gallic acid, further proved to be capable of reducing HIV infectivity in the presence of semen. “Gallic acid is a small molecule found naturally in many foods, including grapes and tea,” says Makhatadze.

LoRicco, Roan, Makhatadze and colleagues further investigated gallic acid’s properties. They used atomic force and confocal microscopies in addition to several quantitative assays to characterize the interaction between gallic acid and the fibrils. Surprisingly, gallic acid did not induce disassembly of the fibrils but instead bound to their surfaces.

The investigators conducted biophysical analysis of fibrils’ surface properties to understand the nature of the interaction. They demonstrated that gallic acid limits the ability of semen fibrils to enhance HIV infection by binding to the fibrils’ surfaces and neutralizing their surface charge. Additionally, the gallic acid-coated fibrils prevent the formation of new amyloid fibrils by binding the precursor components and changing their charge characteristics.

“Gallic acid appears to do two things,” explains Makhatadze. “First, it inhibits new fibril formation. Second, it interacts with pre-existing fibrils and renders them incapable of facilitating HIV infectivity.”

The investigators suggest that gallic acid may be a useful addition to multicomponent microbicides that target both viral and human factors involved in the promotion of HIV transmission and infection. Makhatadze suggests that “such combination microbicides will be more effective at preventing transmission compared to single-component microbicides.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Courtney Chandler

Courtney Chandler is a biochemist and microbiologist in Baltimore, Md., and a columnist for ASBMB Today.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Heat shock proteins as a promising breast cancer therapeutic
Journal News

Heat shock proteins as a promising breast cancer therapeutic

March 25, 2026

Researchers unveiled isoform-specific targets on heat shock protein 90 which may be beneficial in therapeutic development.

Optimized proteomic analysis of preserved biological tissue samples
Journal News

Optimized proteomic analysis of preserved biological tissue samples

March 25, 2026

Researchers have developed an optimized workflow for analyzing formalin-fixed paraffin-embedded tissue. This workflow provides an enhanced collection of unique proteins and phosphorylation sites for more detailed analysis of biological samples.

Blood proteomics reveals fungal infection signatures for faster diagnosis
Journal News

Blood proteomics reveals fungal infection signatures for faster diagnosis

March 24, 2026

Whole-blood proteomics identifies more than 3,000 host and 160 fungal proteins during cryptococcal infection, offering potential biomarkers for faster diagnosis and improved monitoring without invasive spinal taps.

When things get SAPpy: Novel insights into complement
Journal News

When things get SAPpy: Novel insights into complement

March 20, 2026

Researchers have defined interactions between an innate immune protein and two of its known binding partners. They identified potential areas of crosstalk between the two binding interactions.

Glutathione pathway implicated in rare disease
Journal News

Glutathione pathway implicated in rare disease

March 19, 2026

Researchers found that glutathione metabolism plays a central role in the pathogenesis of rare disease methylmalonic aciduria using a novel multiomics approach.

A p-value for proteins
Journal News

A p-value for proteins

March 18, 2026

Kyoto University researchers developed UniScore, a new tool that uses a target-decoy method to filter false positives in proteomic searches, helping scientists set thresholds and improve reliability when analyzing complex protein data.